Alnylam Q2 2021 Earnings Report
Key Takeaways
Alnylam Pharmaceuticals reported a strong second quarter in 2021, achieving combined net product revenues of $161 million for ONPATTRO, GIVLAARI, and OXLUMO. The company also increased its 2021 revenue guidance range to $640-$665 million.
Achieved Second Quarter 2021 Combined Net Product Revenues of $161 Million for ONPATTRO®, GIVLAARI®, and OXLUMO®.
Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN).
Completed Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy (ATTR-CM).
Increased 2021 Guidance Range for Combined Net Product Revenues from $610-$660 Million to $640-$665 Million.
Alnylam
Alnylam
Alnylam Revenue by Segment
Forward Guidance
Alnylam increased its 2021 revenue guidance for combined net product revenues to between $640 million and $665 million and expects net revenues from collaborations and royalties to be between $150 million and $200 million. GAAP R&D and SG&A expenses are expected to be between $1,335 million and $1,455 million. Non-GAAP R&D and SG&A expenses are expected to be between $1,175 million and $1,275 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income